PLI Share Price

Open 2.16 Change Price %
High 2.16 1 Day -0.11 -5.05
Low 2.06 1 Week -0.18 -8.00
Close 2.07 1 Month -0.58 -21.89
Volume 2152215 1 Year -1.26 -37.84
52 Week High 3.57
52 Week Low 1.88
PLI Important Levels
Resistance 2 2.16
Resistance 1 2.12
Pivot 2.10
Support 1 2.02
Support 2 1.98
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
BTO 3.38 1.81%
BTO 3.38 1.81%
SC 60.83 -0.44%
PRE 0.64 0.00%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
DA-A 0.23 35.29%
ANX 0.06 20.00%
ANX 0.06 20.00%
CUM 0.90 13.92%
CUM 0.90 13.92%
CXA-B 1.10 11.11%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
PWC 0.10 -16.67%
PWC 0.10 -16.67%
TOS 2.25 -11.42%
TOS 2.25 -11.42%
BX 0.85 -10.53%
BX 0.85 -10.53%
CET 0.48 -9.43%
CET 0.48 -9.43%
DNT 0.10 -9.09%
More..

ProMetic Life Sciences Inc (TSE: PLI)

PLI Technical Analysis 5
As on 7th Dec 2016 PLI Share Price closed @ 2.07 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.89 & Strong Sell for SHORT-TERM with Stoploss of 2.77 we also expect STOCK to react on Following IMPORTANT LEVELS.
PLI Target for December
1st Target up-side 2.89
2nd Target up-side 3.22
3rd Target up-side 3.54
1st Target down-side 1.97
2nd Target down-side 1.64
3rd Target down-side 1.32
PLI Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.prometic.com
PLI Address
PLI
531 Des Prairies Boulevard
Building 15
Laval, QC H7V 1B7
Canada
Phone: 450-781-0115
Fax: 450-781-4477
Interactive Technical Analysis Chart ProMetic Life Sciences Inc ( PLI TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ProMetic Life Sciences Inc
PLI Business Profile
ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparation, plasma-derived therapeutics, and small-molecule drugs. The company also offers its technologies for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutics products targeting unmet medical needs in the fields of fibrosis, anemia, cancer, and autoimmune disease, as well as plasma-derived therapeutics in orphan drug indications. It operates in two segments, Therapeutics and Protein Technology. The Therapeutics segment’s lead product includes PBI-4050, which targets unmet medical needs, such as the treatment of fibrosis in patients with chronic kidney diseases and certain cancers, and the side effects associated with chemotherapy. This segment also develops PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases; and PBI-1402, a drug candidate for the treatment of anemia indications. The Protein Technology segment provides plasma protein purification system, a solution for the extraction and purification of therapeutic proteins from human plasma; bioseparation products based on applications of its patented Mimetic Ligand technology for various biopharmaceutical companies; and prion capture/pathogen removal technology platform that improves the safety profile of blood products and blood-derived therapeutics. The company was formerly known as Innovon Life Sciences Holdings Limited and changed its name to ProMetic Life Sciences Inc. in May 1998. ProMetic Life Sciences Inc. was founded in 1992 and is headquartered in Laval, Canada.